Print
Email
Print Edition Stories
MHT's Emerging Technologies Forum: Health IT and the Cloud
Connecticut pharmaceutical services company Aptuit Inc. has entered into a partnership with Italy’s Siena Biotech S.p.A. in which Siena Biotech will take a minority stake in Aptuit’s Italian operations in Verona, Italy. Aptuit bought those operations from GlaxoSmithKline earlier this month.
Under the strategic partnership, Aptuit will become a provider of choice for Siena Biotech’s development pipeline, focused in three key therapeutic areas, including Alzheimer’s disease, Huntington’s disease and oncology. No financial terms of the deal were disclosed.
On July 1 Aptuit announced the acquisition of operations at GlaxoSmithKline’s Medicine’s Research Centre in Verona. GSK’s divestment of the Verona facility was tied to its February proposal to cease discovery research in select neurosciences areas such as pain and depression. Greenwich-based Aptuit said at the time that buying the center provides for continued employment of the 500 personnel at the center and that Aptuit can provide GSK with research and development services from the facility.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
